Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A usually slow-growing, grade 1 pancreatic neuroendocrine tumor that secretes serotonin. When it metastasizes to the liver, it produces the clinical symptoms of the carcinoid syndrome.
3 clinical trials registered, 2 recruiting. Interventions under study include drug therapy, other interventions, medical devices, and procedural interventions. Pipeline includes 2 PHASE3, 1 NA. Research is sponsored by a mix of industry and academic institutions.
5 publications have been identified in PubMed for enterochromaffin cell serotonin-producing pancreatic neuroendocrine tumor. Research spans Case Report / Case Series (40%), Review / Meta-Analysis (20%), and Clinical Trial Publication (20%).
Uccella S (2026). [PMID: 41273419](https://pubmed.ncbi.nlm.nih.gov/41273419/). *Virchows Arch*. [Review / Meta-Analysis]
Kumar A (2025). [PMID: 40546570](https://pubmed.ncbi.nlm.nih.gov/40546570/). *Cureus*. [Case Report / Case Series]
Vanoli A (2025). [PMID: 40347392](https://pubmed.ncbi.nlm.nih.gov/40347392/). *Endocr Pathol*. [Clinical Trial Publication]
Asa SL (2024). [PMID: 39034742](https://pubmed.ncbi.nlm.nih.gov/39034742/). *Am J Surg Pathol*. [Epidemiology / Natural History]
Data assembled from 4 of 12 sources · Last updated Sep 21, 2026, 4:53 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center